Marijuana Firm Cresco Labs Expands In Arizona, Illinois

Just weeks after closing a $100 million capital raise, Chicago-based Cresco Labs is growing again – this time through acquisitions in Arizona and Illinois.

The multistate cannabis firm announced that it has acquired Arizona Facilities Supply, which provides management services to Encanto Green Cross Dispensary. Encanto is licensed to cultivate, process and dispense medical marijuana across the state.

The deal adds two cultivation sites, a processing facility and a dispensary to Cresco’s Arizona portfolio, which already includes a cultivation and dispensary operation.

Terms of the deal, which included cash and equity considerations, were not disclosed.

Cresco also signed a definitive agreement to acquire FloraMedex, a medical cannabis dispensary located in the Chicago suburb of Elmwood Park – Cresco’s third acquisition in Illinois.

Cresco Labs also has operations in California, Nevada, Ohio and Pennsylvania.

“Our growth strategy from Day One has been set on having a national footprint,” Cresco CEO and co-founder Charlie Bachtell said.

“With the pending (merger and acquisition) activity we have in the pipeline, we’re on track to enter a majority of the larger states that we’re not in yet.”

The firm has a license pending in Michigan and is targeting additional acquisitions in New York and Florida.

Lisa Bernard-Kuhn can be reached at [email protected]

Original Article Source: https://mjbizdaily.com/cannabis-firm-cresco-labs-expands-in-arizona-illinois/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

A Dozen US Governors Ask Congressional Leaders To Back Federal Marijuana Reform

A bipartisan coalition of 12 governors from states that have legalized medical or recreational cannabis sent a letter to congressional leaders, asking for their support in getting a major marijuana reform bill through the U.S. House and Senate. The governors of California, Colorado, Maryland, Massachusetts, Nevada, New York, North Dakota, Oregon, Pennsylvania, Utah, Vermont and Washington state are backing the STATES Act – which would codify in federal law that marijuana regulations are to be left to the states instead of the federal government – while also seeking protections on banking and tax issues for the MJ industry. “The STATES Act is not about whether marijuana should be legal or illegal; it is about respecting the authority of states to act, lead and respond to the evolving needs and attitudes of their citizens,” the governors wrote. The letter also expressed support for the SAFE Banking Act , which was approved in March by a House committee. Tha...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Norma Pence

Search This Blog